补充多菌种合生素对血脂异常患者血清脂质概况、肠道有益菌丰度和固缩菌与类杆菌比例的影响;一项随机、双盲、安慰剂对照临床试验

IF 2.4 Q3 NUTRITION & DIETETICS PharmaNutrition Pub Date : 2023-12-10 DOI:10.1016/j.phanu.2023.100367
Shekoufeh Salamat , Mohammad Reza Tabandeh , Alireza Jahan-Mihan , Anahita Mansoori
{"title":"补充多菌种合生素对血脂异常患者血清脂质概况、肠道有益菌丰度和固缩菌与类杆菌比例的影响;一项随机、双盲、安慰剂对照临床试验","authors":"Shekoufeh Salamat ,&nbsp;Mohammad Reza Tabandeh ,&nbsp;Alireza Jahan-Mihan ,&nbsp;Anahita Mansoori","doi":"10.1016/j.phanu.2023.100367","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span><span><span><span>Dysbiosis an imbalance of </span>gut microbiota (GM) may contribute to the development of </span>metabolic disorders<span> including dyslipidemia<span>. Synbiotics have been suggested to modulate GM composition and in turn, they may alter </span></span></span>lipid metabolism. We aimed to evaluate the effects of synbiotic supplementation on </span>serum lipid<span><span> profile, abundance of dominant gut bacteria, and also the Firmicutes to </span>Bacteroidetes (F/B) ratio in adults with dyslipidemia.</span></p></div><div><h3>Methods</h3><p><span>Fifty-six adults with dyslipidemia were enrolled in a randomized, clinical trial. Participants were randomly allocated to receive either synbiotic or placebo sachets for 12 weeks. Each synbiotic sachet contains (a total dose of 3 ×10</span><sup>10</sup><span><span><span><span> colony forming units<span>, CFU/gram) six species of probiotic<span> microorganisms with 5-gram inulin and </span></span></span>fructooligosaccharide (FOS) in equal amounts as </span>prebiotics. Serum lipid profile, </span>fecal bacteria<span><span> abundance, dietary intake, physical activity level (PAL), and </span>anthropometric measures, were assessed at the baseline and after intervention.</span></span></p></div><div><h3>Results</h3><p>No significant changes were observed in participants' dietary intake, PA, and anthropometric indices within and between groups after 12 weeks of intervention. High-density lipoprotein-cholesterol (HDL-C) showed a significant increase (p = 0.0008), while no significant change in other lipid profile components was observed. The abundance of fecal <span><em>Firmicutes, Bacteroidetes, </em><em>Lactobacillus</em></span>, and <span><em>Bifidobacterium</em></span> was significantly increased in the synbiotic group (p &lt; 0.0001, p &lt; 0.0001, p &lt; 0.0001, and p = 0.032 respectively). However, 12 weeks of synbiotic supplementation didn’t affect F/B Ratio (p = 0.43) at the end of the study.</p></div><div><h3>Conclusions</h3><p>Twelve weeks of supplementation with multi-species synbiotic may improve HDL-C and enhance the abundance of beneficial gut bacteria in patients with dyslipidemia.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of supplementation with a multi-species synbiotic on serum lipid profile, abundance of beneficial gut bacteria and firmicutes to bacteroidetes ratio in patients with dyslipidemia; a randomized, double-blind, placebo-controlled, clinical trial\",\"authors\":\"Shekoufeh Salamat ,&nbsp;Mohammad Reza Tabandeh ,&nbsp;Alireza Jahan-Mihan ,&nbsp;Anahita Mansoori\",\"doi\":\"10.1016/j.phanu.2023.100367\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><span><span><span><span>Dysbiosis an imbalance of </span>gut microbiota (GM) may contribute to the development of </span>metabolic disorders<span> including dyslipidemia<span>. Synbiotics have been suggested to modulate GM composition and in turn, they may alter </span></span></span>lipid metabolism. We aimed to evaluate the effects of synbiotic supplementation on </span>serum lipid<span><span> profile, abundance of dominant gut bacteria, and also the Firmicutes to </span>Bacteroidetes (F/B) ratio in adults with dyslipidemia.</span></p></div><div><h3>Methods</h3><p><span>Fifty-six adults with dyslipidemia were enrolled in a randomized, clinical trial. Participants were randomly allocated to receive either synbiotic or placebo sachets for 12 weeks. Each synbiotic sachet contains (a total dose of 3 ×10</span><sup>10</sup><span><span><span><span> colony forming units<span>, CFU/gram) six species of probiotic<span> microorganisms with 5-gram inulin and </span></span></span>fructooligosaccharide (FOS) in equal amounts as </span>prebiotics. Serum lipid profile, </span>fecal bacteria<span><span> abundance, dietary intake, physical activity level (PAL), and </span>anthropometric measures, were assessed at the baseline and after intervention.</span></span></p></div><div><h3>Results</h3><p>No significant changes were observed in participants' dietary intake, PA, and anthropometric indices within and between groups after 12 weeks of intervention. High-density lipoprotein-cholesterol (HDL-C) showed a significant increase (p = 0.0008), while no significant change in other lipid profile components was observed. The abundance of fecal <span><em>Firmicutes, Bacteroidetes, </em><em>Lactobacillus</em></span>, and <span><em>Bifidobacterium</em></span> was significantly increased in the synbiotic group (p &lt; 0.0001, p &lt; 0.0001, p &lt; 0.0001, and p = 0.032 respectively). However, 12 weeks of synbiotic supplementation didn’t affect F/B Ratio (p = 0.43) at the end of the study.</p></div><div><h3>Conclusions</h3><p>Twelve weeks of supplementation with multi-species synbiotic may improve HDL-C and enhance the abundance of beneficial gut bacteria in patients with dyslipidemia.</p></div>\",\"PeriodicalId\":20049,\"journal\":{\"name\":\"PharmaNutrition\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2023-12-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PharmaNutrition\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213434423000397\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmaNutrition","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213434423000397","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

摘要

背景:肠道菌群失调(GM)可能导致代谢紊乱,包括血脂异常。合成制剂被认为可以调节转基因成分,进而改变脂质代谢。我们的目的是评估合成菌补充剂对血脂谱、优势肠道细菌丰度以及血脂异常成人厚壁菌门与拟杆菌门(F/B)比值的影响。方法:56名患有血脂异常的成年人参加了一项随机临床试验。参与者被随机分配接受合成或安慰剂包12周。每个合成小袋含有6种益生菌微生物(总剂量为3个×1010菌落形成单位,CFU/克),其中5克菊粉和低聚果糖(FOS)等量作为益生元。在基线和干预后评估血清脂质谱、粪便细菌丰度、饮食摄入量、身体活动水平(PAL)和人体测量值。结果干预12周后,组内及组间受试者的饮食摄入、PA和人体测量指标均无显著变化。高密度脂蛋白-胆固醇(HDL-C)显著升高(p = 0.0008),而其他脂质组分无显著变化。合成菌组粪便中厚壁菌门、拟杆菌门、乳酸杆菌和双歧杆菌的丰度显著增加(p <0.0001, p <0.0001, p <0.0001, p = 0.032)。然而,在研究结束时,补充12周的合成菌没有影响F/B比(p = 0.43)。结论补充多菌种合成菌12周可改善血脂异常患者的HDL-C水平,提高有益肠道菌群的丰度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The effect of supplementation with a multi-species synbiotic on serum lipid profile, abundance of beneficial gut bacteria and firmicutes to bacteroidetes ratio in patients with dyslipidemia; a randomized, double-blind, placebo-controlled, clinical trial

Background

Dysbiosis an imbalance of gut microbiota (GM) may contribute to the development of metabolic disorders including dyslipidemia. Synbiotics have been suggested to modulate GM composition and in turn, they may alter lipid metabolism. We aimed to evaluate the effects of synbiotic supplementation on serum lipid profile, abundance of dominant gut bacteria, and also the Firmicutes to Bacteroidetes (F/B) ratio in adults with dyslipidemia.

Methods

Fifty-six adults with dyslipidemia were enrolled in a randomized, clinical trial. Participants were randomly allocated to receive either synbiotic or placebo sachets for 12 weeks. Each synbiotic sachet contains (a total dose of 3 ×1010 colony forming units, CFU/gram) six species of probiotic microorganisms with 5-gram inulin and fructooligosaccharide (FOS) in equal amounts as prebiotics. Serum lipid profile, fecal bacteria abundance, dietary intake, physical activity level (PAL), and anthropometric measures, were assessed at the baseline and after intervention.

Results

No significant changes were observed in participants' dietary intake, PA, and anthropometric indices within and between groups after 12 weeks of intervention. High-density lipoprotein-cholesterol (HDL-C) showed a significant increase (p = 0.0008), while no significant change in other lipid profile components was observed. The abundance of fecal Firmicutes, Bacteroidetes, Lactobacillus, and Bifidobacterium was significantly increased in the synbiotic group (p < 0.0001, p < 0.0001, p < 0.0001, and p = 0.032 respectively). However, 12 weeks of synbiotic supplementation didn’t affect F/B Ratio (p = 0.43) at the end of the study.

Conclusions

Twelve weeks of supplementation with multi-species synbiotic may improve HDL-C and enhance the abundance of beneficial gut bacteria in patients with dyslipidemia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
PharmaNutrition
PharmaNutrition Agricultural and Biological Sciences-Food Science
CiteScore
5.70
自引率
3.10%
发文量
33
审稿时长
12 days
期刊最新文献
Advancements in psoriasis management: Integrating nutrient supplement with gut-brain-skin connection Can L-Methionine and S-Adenosyl-L-Methionine Effectively Mitigate Scopolamine-Induced Cognitive and Motor Deficits in Mice? Melatonin supplementation in preclinical colitis models: A systematic review and dose-response meta-analysis on inflammation, oxidative stress, and colon repair Efficacy and safety of liraglutide on C-reactive protein (CRP) in adults with type 2 diabetes: A GRADE-assessed systematic review and dose-response meta-analysis of controlled trials Editorial Board
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1